NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio
about
Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsAzacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenibFeasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationNational Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committeeSurvival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.The role of second transplants for leukemia.Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challengesSustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report.CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased RelapseCellular therapy following allogeneic stem-cell transplantation.Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation.Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation.Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.Immunotherapy for pediatric leukemia.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsRisk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplDonor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Isolated Granulocytic Sarcoma of the Breast after Allogeneic Stem Cell Transplantation: A Rare Involvement Also Detected by 18FDG-PET/CT.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
P2860
Q28067102-42785A34-981E-4D51-83E7-688E9D417275Q33405278-DB4C4BF2-06EA-4100-B8E7-2B955F30806EQ33772438-3D60A684-9B94-4B9E-837A-62B716D7BF00Q33831349-3D233590-A7F2-468E-B8DE-0D9BCD234862Q34325183-F489A14C-1C05-497B-818A-7CACEEE5FA3BQ34667390-9502611B-AA73-4C06-8088-DE514A53F383Q34861985-A67429E0-9464-4F3E-878C-C0478A22219DQ35008021-54F28D4B-726F-4947-88E3-3EA4CA269118Q35085209-0D054135-BA79-4B45-AFFE-14B4C4CDC538Q35100974-C94A3919-0126-4757-9F7E-C85F3AD542B3Q35585983-A3CD71B0-094E-40D6-A554-6F3DD000CDA8Q35640788-E9D336E6-4D64-4908-82CA-A560A1BB09BFQ35752737-EFEC0EE5-2F59-4AF0-8E3D-B1E6D53CA2C5Q35847466-6565862C-66EA-4543-913E-14E5D592A1C2Q36204850-26D7BA2F-83F8-4CE5-8B8F-4C7DB5DA8AA6Q36266642-E6469243-DB74-47DE-9E0B-C268770C1EBAQ36581381-7381EF4C-158B-4BB5-B9C5-7E6A0211E16BQ36608689-4FF873BF-10D2-4FCE-ABE8-77E8AB421538Q36612643-E3BDED48-1257-4A7A-A500-AC7AAE46B1E2Q36623397-3ED562A4-D7EF-4C9B-9A66-F0AFCC3C12AEQ36708930-4A65812E-D0E1-49D8-99E1-94714BBCA1E3Q36712059-B1F733A1-0E4A-4EE7-BC26-5E099773E798Q36741749-A9ED455D-1ACE-4FB4-82F7-7475276E7E5DQ36968163-4B544AFB-FE04-46BD-9F63-73836944CB9EQ37000485-10B9C62B-061F-42C0-82F5-7F894CFB7CD6Q37123927-DA883E87-182C-4BF3-B713-BFF0845A4BC0Q37148120-B1B3B675-2360-4A2D-B426-8A99F7FEAC65Q37212916-F4EDA2BF-4756-42D3-93B1-536FE7C42454Q37359736-6402E0F7-9309-452F-B6A9-9876A9E712AFQ37390239-8BADBE7B-E4B4-44C5-A71A-A71AD48084EBQ37431934-04AB3D49-EB56-4518-87A0-60B22730B79CQ37609957-9EF4C231-E6BF-4C58-A551-D51F67EC4D60Q37832506-A0BA2522-13FF-435E-BB88-FE31D7550320Q37938531-2C318996-4509-46A1-823B-CA3A90FEECC6Q38803361-49A9ABEE-466F-4CE1-9D26-AA842A4FFCAFQ38914652-29B05897-CAC4-47C8-A37E-7EC4A51E8BFBQ39039017-D2CCB134-6343-45D2-8BB5-434986876888Q40049548-101D0E80-4599-41AF-98BA-9112097D7895Q40313702-E990874C-523D-4F54-8771-1982C6AA2AF7Q40454294-F4D4F0C6-2652-46D5-B212-F74D533E04BB
P2860
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@ast
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@en
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@nl
type
label
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@ast
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@en
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@nl
prefLabel
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@ast
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@en
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@nl
P2093
P2860
P1476
NCI First International Worksh ...... ietic Stem Cell Transplantatio
@en
P2093
Alan S Wayne
David L Porter
Edwin P Alyea
J H Frederik Falkenburg
Jacob M Rowe
John Levine
Joseph H Antin
Karl Peggs
P2860
P304
P356
10.1016/J.BBMT.2010.08.001
P577
2010-08-10T00:00:00Z